Evaluation of p16INK4a as a diagnostic tool in the triage of pap smears demonstrating atypical squamous cells of undetermined significance

Cancer

Volumn 114, Issue 1, 2008, Pages 34-48

  Duncan, Lisa ^a   Jacob, Sanjivini ^a   Hubbard, Elizabeth ^a  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

ASCUS; Human papillomavirus; Hybrid capture 2; p16

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EMERGENCY HEALTH SERVICE; FEMALE; FOLLOW UP; HOSPITAL COST; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PATHOLOGIST; PRIORITY JOURNAL; SQUAMOUS CELL; STATISTICAL SIGNIFICANCE; UTERINE CERVIX CANCER; ALPHAPAPILLOMAVIRUS; EVALUATION; ISOLATION AND PURIFICATION; METHODOLOGY; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ADOLESCENT; ADULT; AGED; ALPHAPAPILLOMAVIRUS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 39749195507     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23255     Document Type: Article

References (56)

1. World Health Organization. Comprehensive Cervical Cancer Control: A Guide to Essential Practice. Geneva, Switzerland: WHO; 2006.
2. Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med. 2003;127:946-949.
3. Papanicolaou G. A new procedure for staining vaginal smears. Science. 1942;95:438-439.
4. Koss L. The Papanicolaou test for cervical cancer detection: a triumph and a tragedy. JAMA. 1989;261:737-743.
5. Walboomers J, Jacobs M, Manos M, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
6. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA and its prevalence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984;3:1151-1157.
7. Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A. 1983;80:3812-3815.
8. Munger K, Phelps W, Bubb V, Howley P, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 are necessary and sufficient for transformation of primary human keratinocytes. J Virol. 1989;63:4417-4421.
9. Munger K, Werness B, Dyson N, Phelps W, Harlow E, Howley P. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 1989;8:4099-4105.
10. Dyson N, Howley P, Munger K, Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243:934-937.
11. Chen P, Scully P, Shew J, Wang J, Lee W. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell. 1989;58:1193-1198.
12. DeCaprio J, Ludlow J, Lynch D, et al. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell. 1989;58:1085-1095.
13. Mihara K, Cao X, Yen A, et al. Cell cycle dependent regulation of phosphorylation of the human retinoblastoma gene product. Science. 1989;246:1300-1303.
14. Sherr C. The ins and outs of RB: coupling gene expression to the cell cycle clock. Trends Cell Biol. 1994;4:15-18.
15. Helin K, Ed H. The retinoblastoma protein as a transcriptional repressor. Trends Cell Biol. 1993;3:43-46.
16. LaThangue N. DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell cycle control. Trends Biochem Sci. 1994;19:108-114.
17. Nevins J. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science. 1992;258:424-429.
18. Werness B, Levine A, Howley P. Association of human papillomavirus types 16 and 18 E6 oncoproteins with p53. Science. 1990;248:76-79.
19. Scheffner M, Huibregtse J, Viestra R, Howley P. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitinization of p53. Cell. 1993;75:495-505.
20. Serrano M, Hannon G, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704-707.
21. Kamb A, Gruis N, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.
22. Nobori T, Miura K, Wu K, Lois A, Takabayashi K, Carson D. Deletions of the cyclin dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994;368:753-756.
23. Khleif S, DeGregori J, Yee C, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A. 1996;93:4350-4354.
24. Li Y, Nichols M, Shay J, Xiong Y. Transcriptional repression of the D-type cyclin dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 1994;54:6078-6082.
25. Fahey M, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol. 1995;141:680-689.
26. Nanda K, McCrory D, Myers E. Accuracy of the Papanicolaou test in screening for and follow up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132:810-819.
27. Klinkhamer P, Meerding W, Rosier P, Hanselaar A. Liquid based cervical cytology. Cancer. 2003;99:263-271.
28. Solomon D, Schiffman M, Tarone R. Comparison of 3 management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299.
29. Franco E. Chapter 13: primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr. 2003:89-96.
30. Lorincz A, Richart R. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med. 2003;127:959-968.
31. Bibbo M, Klump W, DeCecco J, Kovatich A. Procedure for immunocytochemical detection of p16INK4a antigen in thin-layer, liquid based specimens. Acta Cytol. 2002;46:25-29.
32. Saqi A, Pasha T, McGrath C, Yu G, Zhang P, Gupta P. Overexpression of p16INK4a in liquid based specimens (Sure-Path trade mark) as marker of cervical dysplasia and neoplasia. Diagn Cytopathol. 2002;27:365-370.
33. Murphy N, Ring M, Killalea A, et al. p16INK4a as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol. 2003;56:56-63.
34. Pientong C, Ekalaksananan T, Kongyingyoes B, et al. Immunocytochemical staining of p16INK4a protein from conventional Pap test and its association with human papillomavirus infection. Diagn Cytopathol. 2004;31:235-242.
35. Meyer J, Hanlon D, Andersen B, Rasmussen O, Bisgaard K. Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtec p16INK4a assay. Cancer Cytopathol. 2007;111:83-92.
36. Liu H, Shi J, Wilkerson M, et al. Immunohistochemical detection of p16INK4a in liquid based cytology specimens on cell block sections. Cancer Cytopathol. 2007;111:74-82.
37. Keating J, Cyiko A, Riethdorf S. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papillomavirus related cervical neoplasia. Am J Surg Pathol. 2001;25:884-891.
38. Hirama T, Miller C, Wilczynski S, Koeffler H. p16 (CDKN2/cyclin dependent kinase 4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines. Mod Pathol. 1996;9:26-31.
39. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol. 1998;153:1741-1748.
40. Nieh S, Chen S, Chu T, et al. Is p16INK4A expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies. Gynecol Oncol. 2005;97:35-40.
41. Kong C, Balzer B, Troxell M, Patterson B, Longacre T. p16 INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high risk HPV in atypical squamous metaplasia. Am J Surg Pathol. 2007;31:33-43.
42. Ekalaksananan T, Pientong C, Sriamporn S, et al. Usefulness of combining testing for p16 protein and human papillomavirus (HPV) in cervical carcinoma screening. Gynecol Oncol. 2006;103:62-66.
43. Trunk M, Dallenbach-Hellweg G, Ridder R, et al. Morphologic characteristics of p16INK4A positive cells in cervical cytology samples. Acta Cytol. 2004;48:771-782.
44. Pientong C, Ekalaksananan T, Swadpanich U, et al. Immunocytochemical detection of p16INK4A protein in scraped cervical cells. Acta Cytol. 2003;47:616-623.
45. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276-284.
46. Nieh S, Chen S, Chu T, Lai H, Fu E. Expression of p16INK4a in pap smears containing atypical glandular cells from the uterine cervix. Acta Cytol. 2004;48:173-180.
47. Akpolat I, Smith D, Ramzy I, Chirala M, Mody D. The utility of p16INK4a and Ki-67 staining on cell blocks prepared from residual thin layer cervicovaginal material. Cancer Cytopathol. 2004;102:142-149.
48. Negri G, Vittadella F, Romano F, et al. p16INK4a expression and progression risk of low grade intraepithelial neoplasia of the cervix uteri. Virchows Arch. 2004;445:616-620.
49. Carozzi F, Cecchini S, Confortini M, et al. Role of p16INK4a expression in identifying CIN2 or more severe lesion among HPV positive patients referred for colposcopy after abnormal cytology. Cancer Cytopathol. 2006;108:119-123.
50. Wentzensen N, Bergeron Ch, Cas F, Eschenbach D, Vinokurova S, von Knebel Doeberitz M. Evaluation of a nuclear score for p16INK4a stained cervical squamous cells in liquid based cytology samples. Cancer Cytopathol. 2005;105:461-467.
51. Nieh S, Chen S, Chu T, Lai H, Fu E. Expression of p16ONK4a in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix. Gynecol Oncol. 2003;91:201-208.
52. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119.
53. Wright T, Cox J, Massad L, Twiggs L, Wilkinson E. 2001 consensus guidelines for the management of women with cervical abnormalities. JAMA. 2001;287:2120-2129.
54. Wright T, Schiffman M, Solomon D. Interim guidance for the use of human papillomavirus DNS testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103:304-309.
55. Sahebali S, Depuydt C, Segers K. p16INK4a as an adjunct marker in liquid based cervical cytology. Int J Cancer. 2004;108:871-876.
56. Pantanowitz L, Florence R, Goulart R, Otis C. Trichomonas vaginalis p16 immunoreactivity in cervicovaginal Pap tests: a diagnostic pitfall. Diagn Cytopathol. 2005;33:210-213.